Скачать или смотреть 🚨 NVAX Q3 2025 EARNINGS: Surprising Revenue Beat, Wider Loss & New 2025 Outlook

In this video, we dissect Novavax (NVAX) Q3 2025 earnings using our concise 5-slide framework so you can quickly see what actually matters for the stock.

We cover the key numbers, including:

Q3 revenue of ~$70M, beating expectations

GAAP EPS loss of ~-$1.25, missing consensus

Updated 2025 revenue guidance raised to $1.04B–$1.06B

Ongoing cost actions, non-cash charges, and balance sheet position

The strategic impact of the Sanofi partnership and milestone payments
(based on company filings and major coverage).
Reuters
+1

Watch this NVAX earnings deep dive to understand:

How sustainable the revenue beat is

What the widening loss really signals

Whether the raised guidance is credible

Scenario analysis for NVAX as a high-risk vaccine/biotech play

Key risks, dilution concerns, and what to watch into 2026

Timestamps
00:00 Introduction
02:24 At-a-Glance Scorecard
09:14 Engine of Profitability (or Loss)
15:10 Business Segments & Partnerships
19:32 Balance Sheet, Cash Runway & Shareholder Risk
24:16 Forward Outlook, Guidance & Investment Takeaways

If you’re a NVAX investor, trader, or fundamental analyst, this breakdown gives you a clear, numbers-first view of Q3 2025 without the hype.

Subscribe for more real-time earnings breakdowns, risk-focused analysis, and valuation-driven insights.

nvax, nvax stock, novavax, novavax stock, nvax earnings, nvax q3 2025, nvax q3 2025 earnings, novavax earnings, novavax q3 2025 results, nvax earnings analysis, nvax stock analysis, nvax earnings call, biotech stocks, vaccine stocks, growth stocks, earnings breakdown, stockanalytics, nvax guidance, nvax revenue beat, nvax eps miss, nvax sanofi partnership

Hashtags

#NVAX #Novavax #Earnings #Q32025 #StockAnalysis #Biotech #EarningsReport #NVAXStock #Investing #FundamentalAnalysis

Join this channel to get access to perks:
   / @stockanalyticsai